1
|
Kohan A, Hinzpeter R, Kulanthaivelu R, Mirshahvalad SA, Avery L, Tsao M, Li Q, Ortega C, Metser U, Hope A, Veit-Haibach P. Contrast Enhanced CT Radiogenomics in a Retrospective NSCLC Cohort: Models, Attempted Validation of a Published Model and the Relevance of the Clinical Context. Acad Radiol 2024:S1076-6332(24)00053-9. [PMID: 38383258 DOI: 10.1016/j.acra.2024.01.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2023] [Revised: 01/18/2024] [Accepted: 01/23/2024] [Indexed: 02/23/2024]
Abstract
RATIONALE AND OBJECTIVE To develop a radiogenomic predictive model for non-small cell lung cancer (NSCLC) patients studied through contrast enhanced chest computed tomography (CE-CT) targeting the most frequent gene alterations. M&M: A retrospective study of patients with NSCLC imaged with CE-CT before treatment and had their tumor genomics sequenced at our institution was performed. Data was gathered from their imaging studies, their electronic medical records and a web-based database search (cBioPortal.ca). All of the patient data was tabulated for analysis. Two predictive models (M1 & M2) were created using different approaches and a third model was extracted from the literature to also be tested in our population. RESULTS Out of 157 patients, eighty were male (51%) and 124 (79%) had a history of smoking. The three most prevalent genes were KRAS, TP53 and EGFR. The M1 radiomics-only model median AUC were 0.61 (TP53), 0.53 (KRAS) and 0.64 (EGFR) and for M1 radiomics + clinical were 0.61 (TP53), 0.61 (KRAS) and 0.80 (EGFR). The M2 radiomics-only model median AUC were 0.63 (TP53), 0.60 (KRAS) and 0.65 (EGFR) and for M2 radiomics + clinical were 0.64 (TP53), 0.62 (KRAS) and 0.81 (EGFR). The external EGFR radiomic model showed an AUC of 0.69 and 0.86 for the radiomics-only and combined radiomics + clinical respectively. CONCLUSION Our study was able to provide robust predictive radiomics model evaluation for the detection of TP53, KRAS and EGFR. We also compared our performance with an already published model and observed how impactful clinical variables can be on models' performance. CLINICAL RELEVANCE STATEMENT Identifying tumor mutations in patients that can't undergo biopsy is critical for their outcomes. KEYPOINTS • Tumor genomic profiling is critical for treatment selection • CE-CT radiomics produce robust predictive models comparable to those already published • Clinical variables should be considered/included in predictive models.
Collapse
Affiliation(s)
- A Kohan
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada.
| | - R Hinzpeter
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada; Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - R Kulanthaivelu
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - S A Mirshahvalad
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - L Avery
- Department of Biostatistics, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - M Tsao
- University Health Network, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - Q Li
- University Health Network, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, ON, Canada
| | - C Ortega
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - U Metser
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada
| | - A Hope
- Department of Radiation Oncology, University Health Network, University of Toronto, ON, Canada
| | - P Veit-Haibach
- Joint Department of Medical Imaging, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, ON M5G 2C1, Canada
| |
Collapse
|
2
|
Elterman D, Alshak MN, Martinez Diaz S, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terens W, Kohan A, Gonzalez R, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu L, Kaminetsky J, Chughtai B. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. J Endourol 2022; 37:74-79. [PMID: 36070450 PMCID: PMC9810348 DOI: 10.1089/end.2022.0226] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Purpose: To document the effect of the temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Israel) on sexual function from a multicenter, randomized, single-blinded, sham-controlled trial. Materials and Methods: Men were randomized 2:1 between iTind and sham procedure arms. The iTind was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 3, and 12 months postoperatively using the Sexual Health Inventory for Men (SHIM) and International Index of Erectile Function (IIEF). Unblinding occurred at 3 months. Results: We studied 185 men with a mean age of 61.1 ± 6.5 years. There was no difference in SHIM or total IIEF between iTind and sham at 3 months or in the iTind arm at 12 months compared with baseline. Men in the iTind arm without erectile dysfunction at baseline showed an improvement in total IIEF score of +6.07 ± 21.17 points (p = 0.034) at 12 months, in addition to an improvement in ejaculatory function. SHIM scores remained unchanged in all groups, regardless of age, prostate volume, or baseline erectile function. Conclusion: No changes were observed in sexual and ejaculatory function of patients with iTind regardless of a man's age, prostate volume, and baseline sexual function. Clinicaltrials.gov: NCT02506465.
Collapse
Affiliation(s)
- Dean Elterman
- Division of Urology, University Health Network, University of Toronto, Toronto, Canada
| | - Mark N. Alshak
- Department of Urology, Weill Cornell Medicine, New York, New York, USA
| | | | - Neal Shore
- Department of Urology, Carolina Urology Research Center, Myrtle Beach, South Carolina, USA
| | - Marc Gittleman
- Department of Urology, South Florida Medical Research, Miami, Florida, USA
| | - Jay Motola
- Department of Urology, Mt Sinai Hospital, New York, New York, USA
| | - Sheldon Pike
- Department of Urology, St John's Episcopal, New York, New York, USA
| | - Craig Hermann
- Department of Urology, Clinical Research Center of Florida, Miami, Florida, USA
| | - William Terens
- Department of Urology, Premier Urology Group, Edison, New Jersey, USA
| | - Alfred Kohan
- Department of Urology, Integrated Medical Professionals, Long Island, New York, USA
| | - Ricardo Gonzalez
- Department of Urology, Houston Metro Urology, Houston, Texas, USA
| | - Aaron Katz
- Department of Urology, NYU Winthrop Hospital, Long Island, New York, USA
| | - Jeffrey Schiff
- Department of Urology, NYU Winthrop Hospital, Long Island, New York, USA
| | - Evan Goldfischer
- Department of Urology, Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, USA
| | - Ivan Grunberger
- Department of Urology, New York Methodist Hospital, Brooklyn, New York, USA
| | - Le Tu
- Department of Urology, Sherbrooke University Hospital, Sherbrooke, Canada
| | - Jed Kaminetsky
- Department of Urology, Manhattan Medical Research, Manhattan, New York, USA
| | - Bilal Chughtai
- Department of Urology, Weill Cornell Medicine, New York, New York, USA.,Address correspondence to: Bilal Chughtai, MD, Department of Urology, Weill Cornell Medicine, 425 East 61st Street, 12th Floor, New York, NY 10065, USA
| |
Collapse
|
3
|
Evans R, Kohan A, Moldwin R, Radecki D, Geib T, Peters KM. Safety, tolerability, and efficacy of LiRIS 400 mg in women with interstitial cystitis/bladder pain syndrome with or without Hunner lesions. Neurourol Urodyn 2021; 40:1730-1739. [PMID: 34288094 DOI: 10.1002/nau.24702] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 04/01/2021] [Indexed: 01/23/2023]
Abstract
AIMS Two phase 2 studies were conducted to assess the efficacy and safety of lidocaine-releasing intravesical system (LiRIS) in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) with (Study 001; NCT02395042) or without, (Study 002; NCT02411110) Hunner lesions (HL). METHODS Both were multicenter, randomized, double-blind, placebo-controlled, and enrolled women aged ≥18 years. In Study 001, patients were randomized 2:1:1 to LiRIS 400 mg/LiRIS 400 mg, placebo/LiRIS 400 mg, or placebo/placebo for a continuous 28 (2 × 14)-day period. In Study 002, patients were randomized 1:1 to LiRIS 400 mg or placebo for a continuous (single treatment) 14-day period. RESULTS In total, 59 and 131 patients received treatment in Studies 001 and 002, respectively. There was no statistically significant difference in the primary endpoint, the change from baseline to Week 4 of follow-up post-removal in mean daily average bladder numeric rating scale (NRS) pain score in either study (Study 001: placebo/placebo, -1.6; LiRIS/LiRIS, -2.7, p = 0.142; placebo/LiRIS, -2.5, p = 0.319; Study 002: LiRIS -1.2; placebo, -1.5, p = 0.505). There was no statistically significant difference between groups in daily worst NRS pain score, number of micturitions/day or urgency episodes/day. There was no clear trend for reduction in number of HL for LiRIS vs placebo. The frequency of treatment-emergent adverse events was similar between treatment groups in both studies; most were mild or moderate intensity. CONCLUSION These studies did not demonstrate a treatment effect of LiRIS 400 mg compared with placebo, either in patients with IC/BPS with HL, or in those without HL.
Collapse
Affiliation(s)
- Robert Evans
- Urology, Wake Forest Baptist Hospital, Winston-Salem, North Carolina, USA
| | - Alfred Kohan
- Bethpage Division, Advanced Urology Centers of New York, Bethpage, New York, USA
| | - Robert Moldwin
- Urologic Infectious/Inflammatory Diseases, The Arthur Smith Institute for Urology, Lake Success, New York, USA
| | | | - Till Geib
- Specialty Development, AbbVie, Irvine, California, USA
| | - Kenneth M Peters
- Urology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan, USA.,Urology, Beaumont Health, Royal Oak, Michigan, USA
| |
Collapse
|
4
|
Chughtai B, Elterman D, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terrens W, Kohan A, Gonzalez RR, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu LM, Alshak MN, Kaminetzky J. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology 2020; 153:270-276. [PMID: 33373708 DOI: 10.1016/j.urology.2020.12.022] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 12/07/2020] [Accepted: 12/16/2020] [Indexed: 10/22/2022]
Abstract
OBJECTIVE To report the results of a multicenter, randomized, controlled trial with a temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel) compared to sham for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. MATERIALS AND METHODS Men 50 years or older were randomized 2:1 between iTind and sham procedure arms. A self-expanding, temporary nitinol device was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 1.5, 3, and 12 months postoperatively using the IPSS, peak urinary flow rate, residual urine, quality of life, and the International Index of Erectile Function. Unblinding occurred at 3 months. RESULTS A total of 175 men (mean age 61.1 ± 6.5) participated (118 iTind vs 57 sham). A total of 78.6% of patients in the iTind arm showed a reduction of ≥3 points in IPSS, vs 60% of patients in the control arm at 3 months. At 12 months, the iTind group reported a 9.25 decrease in IPSS (P< .0001), a 3.52ml/s increase in peak urinary flow rate (P < .0001) and a 1.9-point reduction in quality of life (P < .0001). Adverse events were typically mild and transient, most Clavien-Dindo grade I or II, in 38.1% of patients in the iTind arm and 17.5% in the control arm. No de novo ejaculatory or erectile dysfunction occurred. CONCLUSION Treatment with the second-generation iTind provided rapid and sustained improvement in lower urinary tract symptoms for the study period while preserving sexual function.
Collapse
Affiliation(s)
- Bilal Chughtai
- Department of Urology, NY-Presbyterian Hospital, Weill Cornell Medical Center, New York, NY.
| | - Dean Elterman
- Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada
| | - Neal Shore
- Carolina Urology Research Center, Myrtle Beach, SC
| | | | | | | | | | | | - Alfred Kohan
- Integrated Medical Professionals, Long Island, NY
| | | | | | | | | | | | - Le Mai Tu
- Sherbrooke University Hospital, Sherbrooke, Quebec, Canada
| | | | | |
Collapse
|
5
|
Tullman M, Chartier-Kastler E, Kohan A, Keppenne V, Brucker BM, Egerdie B, Mandle M, Nicandro JP, Jenkins B, Denys P. Low-dose onabotulinumtoxinA improves urinary symptoms in noncatheterizing patients with MS. Neurology 2018; 91:e657-e665. [PMID: 30030330 PMCID: PMC6105039 DOI: 10.1212/wnl.0000000000005991] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2017] [Accepted: 05/14/2018] [Indexed: 11/15/2022] Open
Abstract
Objective To evaluate the efficacy and safety of onabotulinumtoxinA 100 U in noncatheterizing patients with multiple sclerosis (MS) with urinary incontinence (UI) due to neurogenic detrusor overactivity (NDO). Methods In this randomized, double-blind phase III study, patients received onabotulinumtoxinA 100 U (n = 66) or placebo (n = 78) as intradetrusor injections via cystoscopy. Assessments included changes from baseline in urinary symptoms, urodynamics, and Incontinence–Quality of Life (I-QOL) total score. Adverse events (AEs) were assessed, including initiation of clean intermittent catheterization (CIC) due to urinary retention. Results OnabotulinumtoxinA vs placebo significantly reduced UI at week 6 (−3.3 episodes/day vs −1.1 episodes/day, p < 0.001; primary endpoint). Significantly greater proportions of onabotulinumtoxinA-treated patients achieved 100% UI reduction (53.0% vs 10.3%, p < 0.001). Significant improvements in urodynamics (p < 0.01) were observed with onabotulinumtoxinA. Improvements in I-QOL score were significantly greater with onabotulinumtoxinA (40.4 vs 9.9, p < 0.001) and ≈3 times the minimally important difference (+11 points). The most common AE was urinary tract infection (25.8%). CIC rates were 15.2% for onabotulinumtoxinA and 2.6% for placebo. Conclusion In noncatheterizing patients with MS, onabotulinumtoxinA 100 U significantly improved UI and quality of life with lower CIC rates than previously reported with onabotulinumtoxinA 200 U. ClinicalTrials.gov identifier: NCT01600716. Classification of evidence This study provides Class I evidence that compared with placebo, 100 U onabotulinumtoxinA intradetrusor injections significantly reduce UI and improve quality of life in noncatheterizing patients with MS and NDO.
Collapse
Affiliation(s)
- Mark Tullman
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France.
| | - Emmanuel Chartier-Kastler
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Alfred Kohan
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Veronique Keppenne
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Benjamin M Brucker
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Blair Egerdie
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Meryl Mandle
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Jean Paul Nicandro
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Brenda Jenkins
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| | - Pierre Denys
- From the MS Center for Innovations in Care (M.T.), St. Louis, MO; Sorbonne Universités (E.C.-K.), UPMC Paris 6, Pitié Salpétrière Academic Hospital, AP-HP, Paris, UMR Inserm 1179, France; Advanced Urology Centers (A.K.), Bethpage, NY; Université de Liège (V.K.), Belgium; New York University Langone Medical Center (B.M.B), New York; Urology Associates/Urologic Medical Research (B.E.), Kitchener, Ontario, Canada; Evidence Scientific Solutions (M.M.), Philadelphia, PA; Allergan plc (J.P.N., B.J.), Irvine, CA; and Hôpital Raymond Poincaré (P.D.), Garches, UVSQ, UMR Inserm 1179, France
| |
Collapse
|
6
|
Herschorn S, Kohan A, Aliotta P, McCammon K, Sriram R, Abrams S, Lam W, Everaert K. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial. J Urol 2017; 198:167-175. [DOI: 10.1016/j.juro.2017.01.069] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/24/2017] [Indexed: 11/25/2022]
Affiliation(s)
| | - Alfred Kohan
- Advanced Urology Centers of New York, Bethpage, New York
| | - Philip Aliotta
- Western New York Urology Associates, Williamsville, New York
| | | | | | | | | | | |
Collapse
|
7
|
Cruz F, Denys P, Keppenne V, Kohan A, Brucker B, Egerdie B, Magyar A, Nicandro J, Jenkins B, Chartier-Kastler E. Efficacy and safety of onabotulinumtoxina 100 U for treatment of urinary incontinence due to neurogenic detrusor overactivity in noncatheterizing multiple sclerosis patients. Toxicon 2016. [DOI: 10.1016/j.toxicon.2016.11.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Rovner E, Kohan A, Chartier-Kastler E, Jünemann KP, Del Popolo G, Herschorn S, Joshi M, Magyar A, Nitti V. Long-Term Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity Who Completed 4 Years of Treatment. J Urol 2016; 196:801-8. [PMID: 27091236 DOI: 10.1016/j.juro.2016.04.046] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/04/2016] [Indexed: 10/21/2022]
Abstract
PURPOSE We assessed the year-to-year consistency of outcomes in patients with urinary incontinence due to neurogenic detrusor overactivity who completed 4 years of onabotulinumtoxinA treatment. MATERIALS AND METHODS Eligible patients who completed a 52-week phase 3 trial of onabotulinumtoxinA for urinary incontinence could enter a 3-year open label extension study of onabotulinumtoxinA 200 or 300 U administered as needed for symptom control. This analysis focused on 227 patients who completed the 4-year study. Outcomes assessed by year of treatment included mean treatments per year, mean change from baseline at week 6 in urinary incontinence episodes per day and the I-QOL (Incontinence Quality of Life) total summary score, the proportion of patients with 50% or greater and 100% reductions in urinary incontinence episodes per day, duration of effect and adverse events. RESULTS Patients reported 4.3 urinary incontinence episodes per day at baseline and received 1.4 to 1.5 onabotulinumtoxinA treatments per year. The decrease in urinary incontinence following onabotulinumtoxinA consistently ranged from -3.4 to -3.9 episodes per day across 4 years. A high proportion of patients achieved 50% or greater and 100% urinary incontinence reductions in each year (range 86.6% to 94.1% and 43.6% to 57.4%, respectively). Consistent and clinically relevant improvements in I-QOL scores were observed in each treatment year. The overall median duration of effect of onabotulinumtoxinA was 9.0 months or greater (range 3.0 to 49.2) and 26.0% or more of patients experienced a duration of effect of 12 months or greater. The most common adverse event was urinary tract infection with no increased incidence with time. CONCLUSIONS Patients with neurogenic detrusor overactivity who completed 4 years of onabotulinumtoxinA treatment experienced a consistent duration of treatment effect and year-to-year improvements in urinary incontinence and quality of life with no new safety signals.
Collapse
Affiliation(s)
- Eric Rovner
- Department of Urology, Medical University of South Carolina, Charleston, South Carolina.
| | - Alfred Kohan
- Advanced Urology Centers of New York, Bethpage, New York
| | | | - Klaus-Peter Jünemann
- Department of Urology and Pediatric Urology, Klinik für Urologie und Kinderurologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Giulio Del Popolo
- Department of Neurourology, Careggi University Hospital, Florence, Italy
| | - Sender Herschorn
- Division of Urology, University of Toronto, Toronto, Ontario, Canada
| | | | | | - Victor Nitti
- Department of Urology, New York University School of Medicine, New York, New York
| |
Collapse
|
9
|
Serrano E, Ocantos J, Kohan A, Kisilevsky N, Napoli N, García-Mónaco R. Resonancia magnética de próstata: utilidad de la secuencia de difusión en la detección de isquemia postembolización en pacientes con hiperplasia prostática benigna. Radiología 2016; 58:129-35. [DOI: 10.1016/j.rx.2015.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Revised: 08/14/2015] [Accepted: 08/20/2015] [Indexed: 11/24/2022]
|
10
|
Serrano E, Ocantos J, Kohan A, Kisilevsky N, Napoli N, García-Mónaco R. Magnetic resonance imaging of the prostate: usefulness of diffusion sequences in detecting postembolization ischemia in patients with benign prostatic hyperplasia. Radiología (English Edition) 2016. [DOI: 10.1016/j.rxeng.2016.03.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
11
|
Partovi S, Kohan A, Vercher-Conejero JL, Rubbert C, Margevicius S, Schluchter MD, Gaeta C, Faulhaber P, Robbin MR. Qualitative and quantitative performance of ¹⁸F-FDG-PET/MRI versus ¹⁸F-FDG-PET/CT in patients with head and neck cancer. AJNR Am J Neuroradiol 2014; 35:1970-5. [PMID: 24924545 DOI: 10.3174/ajnr.a3993] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND AND PURPOSE MR imaging and PET/CT are integrated in the work-up of head and neck cancer patients. The hybrid imaging technology (18)F-FDG-PET/MR imaging combining morphological and functional information might be attractive in this patient population. The aim of the study was to compare whole-body (18)F-FDG-PET/MR imaging and (18)F-FDG-PET/CT in patients with head and neck cancer, both qualitatively in terms of lymph node and distant metastases detection and quantitatively in terms of standardized uptake values measured in (18)F-FDG-avid lesions. MATERIALS AND METHODS Fourteen patients with head and neck cancer underwent both whole-body PET/CT and PET/MR imaging after a single injection of (18)F-FDG. Two groups of readers counted the number of lesions on PET/CT and PET/MR imaging scans. A consensus reading was performed in those cases in which the groups disagreed. Quantitative standardized uptake value measurements were performed by placing spheric ROIs over the lesions in 3 different planes. Weighted and unweighted κ statistics, correlation analysis, and the Wilcoxon signed rank test were used for statistical analysis. RESULTS κ statistics for the number of head and neck lesion lesions counted (pooled across regions) revealed interreader agreement between groups 1 and 2 of 0.47 and 0.56, respectively. Intrareader agreement was 0.67 and 0.63. The consensus reading provided an intrareader agreement of 0.63. For the presence or absence of metastasis, interreader agreement was 0.85 and 0.70. The consensus reading provided an intrareader agreement of 0.72. The correlations between the maximum standardized uptake value in (18)F-FDG-PET/MR imaging and (18)F-FDG-PET/CT for primary tumors and lymph node and metastatic lesions were very high (Spearman r = 1.00, 0.93, and 0.92, respectively). CONCLUSIONS In patients with head and neck cancer, (18)F-FDG-PET/MR imaging and (18)F-FDG-PET/CT provide comparable results in the detection of lymph node and distant metastases. Standardized uptake values derived from (18)F-FDG-PET/MR imaging can be used reliably in this patient population.
Collapse
Affiliation(s)
- S Partovi
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| | - A Kohan
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| | - J L Vercher-Conejero
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| | - C Rubbert
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| | - S Margevicius
- Department of Biostatistics and Epidemiology (S.M., M.D.S.), Case Western Reserve University, Cleveland, Ohio
| | - M D Schluchter
- Department of Biostatistics and Epidemiology (S.M., M.D.S.), Case Western Reserve University, Cleveland, Ohio
| | - C Gaeta
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| | - P Faulhaber
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| | - M R Robbin
- From the Department of Radiology (S.P., A.K., J.L.V.-C., C.R., C.G., P.F., M.R.R.), University Hospitals Seidman Cancer Center, University Hospitals Case Medical Center, Case Western Reserve University, Cleveland, Ohio
| |
Collapse
|
12
|
Gaeta CM, Vercher-Conejero JL, Sher AC, Kohan A, Rubbert C, Avril N. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Q J Nucl Med Mol Imaging 2013; 57:352-366. [PMID: 24322792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Primary breast cancer often displays only moderately increased glucose metabolism resulting in a low sensitivity of positron emission tomography (PET) using [F-18]fluorodeoxyglucose (FDG) in detecting small breast carcinomas, locoregional micrometastases and non-enlarged tumor infiltrated lymphnodes. In contrast, distant breast cancer metastases are generally characterized by significantly increased metabolic activity compared to normal tissue. Therefore, FDG-PET provides accurate diagnostic information as a whole body imaging modality in staging of breast cancer patients. The metabolic information from FDG-PET/CT is often more sensitive than conventional imaging for the detection of distant metastases, particularly in the recurrent setting. FDG-PET is superior in detecting tumor-involved distant lymphnodes, particularly those which are normal in size, as well as in characterizing enlarged lymphnodes as positive or negative for malignancy. Of note, CT is superior in detecting small lung metastases. Although the overall sensitivity for bone scintigraphy and FDG-PET are comparable, bone scintigraphy seems to be superior in the detection of osteoblastic disease whereas FDG-PET is superior for osteolytic metastases, suggesting a complementary role for both imaging procedures. FDG-PET/MR has an evolving role in breast cancer management, for example in the detection of liver metastases and in the research setting for treatment monitoring. The utilization of PET for prediction of treatment response to primary chemotherapy is an area of active research, using FDG as well as other PET biomarkers including [F-18]Fluoroestradiol, [F-18]Fluorothymidine and integrin targeting tracer for monitoring anti-angiogenic therapy.
Collapse
Affiliation(s)
- C M Gaeta
- University Hospitals Case Medical Center Case Western Reserve University, Cleveland, OH, USA -
| | | | | | | | | | | |
Collapse
|
13
|
Kohan A, Tso P. Current concepts of gastrointestinal (GI) fat sensing focusing on all aspects from luminal, absorptive and postabsorptive in animal models. Appetite 2010. [DOI: 10.1016/j.appet.2010.04.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
14
|
Bertinetti C, Milone G, Kohan A, Saporito G, Robinson A, García JJ, Milone J, Cerutti I, Feldman L, Jarchum G, Bordone J, Koziner B. Cell processing practices in Argentina: report of a multicenter survey. Cytotherapy 2002; 3:127-33. [PMID: 12028835 DOI: 10.1080/14653240152584695] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- C Bertinetti
- Unidad de Investigaciones Oncohematol gicas, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Kohan A, Niborski R, Daruich J, Rey J, Bastos F, Amerise G, Herrera R, García M, Olivera W, Santarelli MT, Avalos JS, Findor J. Erythrocytapheresis with recombinant human erythropoietin in hereditary hemochromatosis therapy: a new alternative. Vox Sang 2001; 79:40-5. [PMID: 10971213 DOI: 10.1159/000031204] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND AND OBJECTIVES The purposes of this study were to evaluate the tolerance, efficacy and safety of isovolemic erythrocytapheresis (EA) in nonanemic patients with hereditary hemochromatosis (HH), and to assess the usefulness of recombinant human erythropoietin (rHuEPO) associated with EA to reduce treatment duration. MATERIALS AND METHODS In 10 asymptomatic patients with serum ferritin >400 microg/l, transferrin saturation >50%, and GPT elevation, EA with rHuEPO and folic acid was performed. RESULTS Red cell indices, serum ferritin, and other iron metabolism parameters (serum iron, transferrin, and transferrin saturation); GPT and other laboratory data were considerably improved. CONCLUSION This method offers better results in less time than traditional phlebotomy. EA with rHuEPO is an effective therapeutic alternative for patients with HH.
Collapse
Affiliation(s)
- A Kohan
- Departments of Transfusion Medicine and Immunotherapy, and Gastroenterology, Hospital de Clínicas, University of Buenos Aires School of Medicine, Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Kusminsky G, Foncuberta MC, Aversa L, Drelichman G, Freigeiro D, Burgos R, Irrazabal C, Gonzalez G, Dictar M, Niborski R, Kohan A, Sanchez Avalos JC. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood]. Medicina (B Aires) 2000; 60:179-87. [PMID: 10962806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Abstract
Fifty three patients (pts) received an allogeneic hematopoietic transplant using peripheral blood progenitor cells (PBPC). Diagnosis were acute myeloid leukemia (AML) in 16 pts, acute lymphoblastic leukemia (ALL) in 15, chronic myeloid leukemia (CML) in first chronic phase in 12, aplastic anemia in 4, myelodysplasia in 3 and Hodgkin's disease, major thalasemia and Hunter's syndrome in one each. Mean age was 20 years-old (2-55), 28 males and 25 females. Conditioning regimens were total body irradiation with 1200 cGy and cyclophosphamide 120 mg/kg in 38 pts, busulfan 16 mg/kg and cyclophosphamide 120 mg/kg in 10 pts, total lymphoid irradiation and cyclophosphamide in 3, 2 pts received other chemotherapy based conditionings. PBPC were infused unmanipulated through a central catheter. Graft versus host disease (GVHD) prophylaxis was cyclosporin and short course methotrexate. Donors were 6/6 HLA compatible siblings in 52 cases and 5/6 match in one case. PBPC mobilization was done with G-CSF at a dose of 10 micrograms/kg/day subcutaneously for four days, pheresis started on day 5. Bone marrow harvest was also done in the first thirty cases. Mean cellularities for CD34, CD3, CD4, CD8, CD56, CD19 (cel x 10(6)/kg) were 4.12; 4.59; 2.57; 1.9; 0.55 and 0.68, respectively. Mean recovery of neutrophils > 500/microL was obtained on day +11 and platelets > 20,000/microL on day +13. Patients were hospitalized for a mean period of 26 days (range 18-39) and days with parenteral antibiotics were 12.2 (5-45). Two pts had venoocclusive disease of the liver. Transplant related mortality was 15%. Acute graft versus host disease (GVHD) was observed in 43.4% of pts, only 5 pts had acute GVHD III or IV. Mean time for aGVHD diagnosis was +23 (8-76). Forty three pts were evaluable for chronic GVHD with a mean follow-up of 18 months (4-39). Chronic GVHD was observed in 26.4% by day +240, only 2 pts developed severe cGVHD. The present experience demonstrates an acceptable incidence for cGVHD; however, taking into account recent reports showing an increase of this complication, it seems reasonable not to perform this procedure for non-malignant diseases in which graft versus malignancy effect is not to be expected.
Collapse
Affiliation(s)
- G Kusminsky
- Unidad de Trasplante de Médula Osea, Instituto Médico Alexander Fleming, Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Gnocchi CA, Yaryour C, Kohan A, De Rosa G, Nadal M. [Renal vascular lesion and microangiopathic hemolytic anemia in systemic lupus erythematosus]. Medicina (B Aires) 1998; 57:200-4. [PMID: 9532830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
A 22 year-old woman with a seven year history of (SLE) was readmitted because of oliguria, edema, dyspnea and arterial hypertension. She had a previous biopsy diagnosis of focal glomerulonephritis, (WHO III b), and had been treated with immunosuppressors and steroids. Laboratory data showed lupus activity, AHM with thrombocytopenia, nephrotic-range proteinuria and renal failure. A second renal biopsy was performed showing diffuse proliferative nephritis, (WHO IV), in association with noninflammatory necrotizing vasculopathy with luminal obliteration. She started with hemodialysis and was subsequently treated with methylprednisolone pulses, plasmapheresis, cyclophosphamide and oral steroids. During the inpatient period, she had generalized seizures, acute lung injury and pulmonary hemorrhage. These complications, the AHM and the thrombocytopenia receded totally. Renal function was never resumed. We emphasize that this association of diffuse proliferative nephritis with noninflammatory necrotizing vasculopathy is not infrequent and has a poor renal prognosis. The AHM with thrombocytopenia was interpreted as secondary to endothelial cell damage due to vasculopathy.
Collapse
Affiliation(s)
- C A Gnocchi
- Quinta Cátedra de Medicina Interna, Universidad de Buenos Aires
| | | | | | | | | |
Collapse
|
18
|
Findor JA, Sordá JA, Rey J, Fernández J, Kohan A, Díaz Lestrem M. [Hepatitis B (HBV) and C (HBC) virus infections in Down's syndrome and in neuropsychiatric patients without Down's syndrome]. G E N 1992; 46:208-12. [PMID: 1340826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
UNLABELLED Hepatitis B virus (HBV) markers are found with high frequency in immunocompromised individuals. In order to find out if this is also true for the hepatitis C virus (HCV), we have analyzed a group (G.1) of 46 patients (pts.) with Down syndrome, situation known to be associated with immunodepression G. 1. We compared them with a G. of 310 mentally retarded pts. without Down syndrome G. 2 and without evidence of immunological disfunction. All of them were studied for infection with HBV. All pts. in G. 1 and G. 2 were also tested for HCV. The pts. have been hospitalized in a specialized medical institution for mentally retarded on a long term basis and were followed during 1 year. Finally G 3 was composed of 5454 voluntary blood donors. MATERIAL AND METHODS In all pts. search for HBV infection markers (anti-HBc, HBsAg, HBeAg by EIA test and HBV-DNA by nucleic acids hybridization) were performed. Search for HCV markers was done by a second generation EIA kit (Abbott Hepatitis C (rDNA) (Antigen). RESULTS HBsAg was found to be positive in 12/46 (26%) of G. I and 25/310 (8%) of G. II (p < 0.001). HBeAg was positive in 8/12 (67%) of G. I and in 2/25 (8%) of G. II (p < 0.001). All HBeAg positive pts. had elevated values of DNA-HBV. In G. I, 4/12 (33%) pts. lost HBeAg during the observation period, one of them remained HBV-DNA positive and none become HBsAg negative.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- J A Findor
- Hospital de Clínicas José de San Martín, Buenos Aires, Argentina
| | | | | | | | | | | |
Collapse
|
19
|
Gallo A, Kohan A, Schele C, Gonzalez C, Musoz H, Johnson I, Jentsen G, Sepulveda L, Terraza F. [Use of soybean flour in infant nutrition]. Rev Chil Pediatr 1971; 42:433-42. [PMID: 5167609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
20
|
Tuchszer S, Levin H, Fiszlejder L, Pattin I, Kohan A. [Iatrogenic Pautrier's melanosis]. Prensa Med Argent 1969; 56:496-8. [PMID: 5821574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
|
21
|
Berconsky I, Rapaport S, Kohan A, Nijensohn CM. [Furosemide: a new diuretic derivative of anthranilic acid]. Arch Enferm Coraz Vasos 1965; 68:602-9. [PMID: 5853652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|